Selling Alphabet-C, Amazon, and Eli Lilly, buying gold stocks, and still holding the largest position in NVIDIA. What did the "Soros comrade" see?
Drukenmiller's stock investment portfolio performed strongly in the previous quarter, with the total market value of his holdings increasing by over 20% to nearly $3.4 billion.
Latest exposure of global top family office holdings.
According to the 13F filing submitted this Wednesday, Stanley Druckenmiller's family office, the former deputy of Soros and billionaire, sold stocks of Alphabet-C, Amazon, and Broadcom, while buying stocks of gold miners Barrick and Newmont, which have been heavily hit.
The filing shows that as of December 31, 2023, artificial intelligence remains a prominent theme in Druckenmiller's investment portfolio. The family office not only purchased stocks of AI-related companies Adobe and Arista Networks, but also bought 64,715 shares of Palo Alto Networks.
It is worth mentioning that NVIDIA is Druckenmiller's largest holding, with his fund holding nearly $550 million worth of NVIDIA**, accounting for approximately 16% of his total equity.
Last year, Druckenmiller saw NVIDIA as an investment opportunity in the field of artificial intelligence, but later in the fall, he stated that the stock was already "overheated". Since then, NVIDIA's stock price has almost doubled. According to FactSet data, NVIDIA's stock price has risen by nearly 50% since the beginning of 2024 alone.
Druckenmiller gained fame for his collaboration with George Soros, and over a decade ago, his company stopped accepting funds from external investors. However, his views on the market continue to be sought after by financial media, professional investors, and amateur enthusiasts.
Druckenmiller's decision to sell Alphabet-C stock has attracted attention, as he had just bought the stock in the third quarter of 2023.
In addition, he also sold about 50,000 shares of Eli Lilly. According to FactSet data, in the past few months, Eli Lilly has gained market popularity with its weight loss and diabetes drugs Zepbound and Mounjaro, making it one of the top 10 most valuable companies in the S&P 500 index.
Overall, Druckenmiller's stock investment portfolio performed strongly in the previous quarter, with the total market value of his holdings increasing by over 20% to nearly $3.4 billion.
